Exploring the next generation of antibody–drug conjugates

Tumour heterogeneity and resistance to cancer therapies

Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395

Strategies and challenges for the next generation of antibody–drug conjugates

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Prodrugs: design and clinical applications

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D.-M., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,681

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Junutula, J. R., Raab, H. E., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,388

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209

Biomimetic bispecific antibody-drug conjugates based on albumin binding domain fusing nanobodies targeting EGFR and HER2

Chen, Z., Song, X., Zheng, Y., Zhang, S., Yu, R., & Zhang, C. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119016 · Cited by 1

Microscale native size exclusion chromatography high resolution mass spectrometry for the determination of the chelator-to-antibody ratio of immunoconjugates

van der Zon, A. A. M., Weijers, B., Vugts, D. J., & Gargano, A. (2026) · Analytica Chimica Acta · doi:10.1016/j.aca.2026.345214 · Cited by 1

One‐Step Assembly of Homogeneous DAR4 ADCs via a Traceless Fc Ligand‐Directed Acylation Strategy

Zeng, Y., Lin, Y., Sun, Q., Hang, J., Shi, W., Huang, W., & Tang, F. (2026) · ChemMedChem · doi:10.1002/cmdc.202501075 · Cited by 1

Advances in Breast Cancer Research: Immunological, Pathological, and Pharmacological Perspectives for Improving Patient Outcomes

Crocamo, S., dos Santos, E. C., & Abdelhay, E. S. F. W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041902 · Cited by 1

SDC4 is a novel target of the KLF5 transcription factor

Yokoyama, Y., Yamamoto, H., Uomoto, A., Nakayama, C., Yang, R., TSUJIMOTO, M., Kouda, S., Morimoto, Y., Hata, T., Inoue, A., et al. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153515 · Cited by 1

N -Azidoacetylglucosamine (GlcNAz)-Derived Sugar Oxazolines as a New Class of Substrates for Chemoenzymatic Site-Specific Antibody Bioconjugation

Zong, G., Gomozkova, M., Azzam, T., Sundberg, E. J., & Wang, L. (2026) · JACS Au · doi:10.1021/jacsau.5c01772 · Cited by 1

Click chemistry-driven functional nanocarrier engineering: Interdisciplinary progress from precise assembly to personalized theranostics

Ding, C., Zhang, B., Li, K., Wang, Q., Zhang, X., Ma, X., He, Q., Li, Z., Xin, H., Meng, X., et al. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.217743 · Cited by 1

IR700DX-Based Antibody Conjugates: a Unique Tool for Targeted Cancer Phototherapy

Nikitin, T. D., Gulyak, E. L., & Sapozhnikova, K. A. (2026) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162025601946 · Cited by 1

An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer

Esapa, B., Liu, Y., Chenoweth, A. M., Stoker, K., Łabędź, N., Romero-Clavijo, P., Ilieva, K. M., Trendell, J., Navarro‐Llinas, B., Suriawinata, E., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01341-0 · Cited by 1

Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer

Cruz, P., Boixareu, C., Silva, D., Ting, J., Sena, R. H. R., Pang, S. A., Mullings, S., & Minchom, A. (2026) · Cancers · doi:10.3390/cancers18050880 · Cited by 1

Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates

Yamaguchi, A., Hong, J., Li, L., Kobayashi, K., Yamazaki, C. M., Ha, S. Y. Y., Anami, Y., Xiong, W., Liu, J., An, Z., et al. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag011 · Cited by 1

Spatial heterogeneity of antibody–drug conjugate targets in pancreatic ductal adenocarcinoma

Sabtan, D., Eich, M., Loch, F. N., Zuschneid, J. K. P., Möbs, M., Böhme, J., Klauschen, F., Horst, D. A., Dragomir, M. P., Dernbach, G., et al. (2026) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70083 · Cited by 1

Recent advances in protein modification–enabled potential therapeutics

Wei, L., Liang, K., Zhou, Y., & Chen, Y. (2026) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2026.102665 · Cited by 1

Rational Design, Synthesis, and Systematic Evaluation of Redox-Responsive SN-38 Prodrugs for Selective Activation in Hypoxic Tumor Microenvironments

Dong, T., Xu, J., Wang, X., Sun, Z., Wang, S., Fanghui, C., Zhu, H., Zhang, X., Xu, S. X., Zheng, C., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030515 · Cited by 1

From biology to therapy: current standards and emerging strategies in pleural mesothelioma

van Genugten, J. H. L. T., de Gooijer, C. J., & Baas, P. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1778121 · Cited by 1

Evolution of the NCI antibody-drug conjugate portfolio: from chemical engineering to clinical complexity

Zhan, Q., Zeng, W., Shi, H., & Wan, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1773414 · Cited by 1

Spatiotemporal Profiling of Intratumoral Free Payload Distribution via MALDI Imaging Mass Spectrometry: Implications for Drug-to-Antibody Ratio Optimization in Antibody–Drug Conjugates

Cai, T., Li, Z., Yan, Q., Huang, G., Jia, K., Chen, X., Dun, J., Zou, J., Tan, M., Wu, Y. H., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01235-w · Cited by 1

Nanobody-based targeted cancer therapy and immunotherapy: fear not the future

Guo, M.-D., Liao, R., Wang, M.-Y., Wu, L.-J., & Zhang, Y. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01787-9 · Cited by 1

RSPO2-Based Peptibodies Conjugated with Pyrrolobenzodiazepine Dimer or Camptothecin Analogs Demonstrate Potent Antitumor Activity by Targeting the Three Receptors LGR4/5/6 in Colorectal Cancer and Neuroblastoma

Toh, Y., Tu, J., Wu, L., Aldana, A. M., Wen, J. J., Su, L., Yang, B. T., Liang, X., Li, L., Pan, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03826 · Cited by 1

Ambient Temperature Synthesis of Triazole-4-carbaldehyde Reagent by Dimroth Rearrangement Enabling Facile N-Terminal-specific Modification and Immobilization of Proteins

Wang, S., Sumiyoshi, E., Inoue, N., Zheng, X., Noro, S., Hayashi, T., & Onoda, A. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00583 · Cited by 2

Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape

Spitschak, A., Casalegno‐Garduño, R., & Pützer, B. M. (2026) · Biomarker Research · doi:10.1186/s40364-026-00925-z · Cited by 2

Antibody–drug conjugates for infectious and neglected tropical diseases: chemical design principles, target biology, and translational challenges

Reddy, D., Jeena, V., Papo, T. R., & Ohaekenyem, E. C. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1793193 · Cited by 1

Trial watch: antibody-drug conjugates in cancer therapy

Doffe, F., Deng, X., Shen, Z., Xue, E., Schauer, K., Kroemer, G., & Kepp, O. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2667160 · Cited by 1

Antibody–Drug Conjugates Beyond HER2 in Non-Small Cell Lung Cancer (NSCLC): Mechanisms, Emerging Targets, and Future Directions

Ismail, A., Desai, A. P., Simon, G. R., & Boumber, Y. (2026) · Biomolecules · doi:10.3390/biom16050677 · Cited by 1

High-dose biologics and bioconjugates delivery: Integrating molecular optimization with device design and routes of administration

Budhavaram, N. K., Duffy, K. H., Abouzeid, A. H., Bharadwaj, R., Shrestha, N., Echeverri, E. S., Mitchener, C., & Subramony, J. A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115893 · Cited by 1

CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances

Hasani, R., Pourseif, M. M., Alizadeh, E., Tohidkia, M. R., & Rahmati, M. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105444 · Cited by 1

A Bioorthogonal Prodrug–Prodrug Strategy for Dual Activation Via Retro-Cope/Cope Elimination

Huang, Y., Xiang, F., Liu, M., Min, Q., Peng, W., & Ji, X. (2026) · Organic Letters · doi:10.1021/acs.orglett.6c01645 · Cited by 1

Properties of Drug Linkers Affecting Hydrophobic Interaction Chromatography for Determining the Drug-to-Antibody Ratio of Antibody-Drug Conjugates

Kusama, T., Mimura, M., Nakae, R., Ng, S. Y., Shigemoto, R., Hirakura, Y., & Kawasaki, N. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00433 · Cited by 1

Enhanced subcutaneous delivery of antibody-drug conjugates with recombinant human hyaluronidase PH20: pharmacokinetics and tolerability in minipigs

Nolan, R. P., Connor, R. J., Printz, M. A., Wang, Y., Nekoroski, T., Liu, L., Wahl, C., Theuer, C., & Kang, D. W. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02144-3 · Cited by 1

Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection

Jiao, G., Peng, H., Yang, Y., Liu, Y., Liu, X., Hu, Y., Dai, Y., Li, Z., & Zhao, Q. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02685-8 · Cited by 1

Enhanced Efficacy of EGFR-Targeted ADCs via p38-Mediated Noncanonical Endocytosis in EGFR-Mutant Lung Cancer Cells

Otsuyama, K., Morita, S., Sato, M., Zhou, Y., Yokoyama, S., Azuma, K., Kato, Y., Hayashi, R., & Sakurai, H. (2026) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b26-00027 · Cited by 1

CLDN6 in cancer: Biology, clinical significance, and emerging therapeutic strategies

Yang, Z., Li, M., Yang, J., Du, J., Li, S., Qiu, J., Quan, C., & Qu, H. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108276 · Cited by 1

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Lu, S., Xiao, Q., Qian, L., Sun, S., Zhou, Z., Liao, M. Z., & Li, C. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70350 · Cited by 1

ESCRT-mediated membrane remodeling in cancer immune evasion and resistance to immunotherapy: mechanisms, therapeutic vulnerabilities, and translational implications

Wang, H., Gu, Y., Liu, J., Tan, H., Li, J., Li, J., Shi, W., & Zhang, Y. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117007 · Cited by 1

Development of a High-Throughput Size-Exclusion Chromatography–Mass Spectrometry Workflow for Real-Time Monitoring of Bioconjugation of Cysteine-Based Antibody–Drug Conjugates

Zhang, Z., Jin, P.-R., Lin, W., Liang, T., Deyanova, E. G., Gunawan, R. C., & Ren, H. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00182 · Cited by 1

Programmable multivalent aptamer-drug conjugates enable stable tumor targeting and enhanced therapy for advanced bladder cancer

Tao, S., Zhong, Y., Ju, J., Sun, X., Guo, B., Xia, Q., Chen, H., Tian, T., Tan, W., & Lei, H. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124396 · Cited by 1

New biomarkers for antibody-drug conjugates in lung cancer the pathologist’s perspective

Hofman, V., Rignol, G., Mograbi, B., Ilié, M., Riudavets, M., López‐Ríos, F., Fusco, N., Malapelle, U., Popat, S., Stenzinger, A., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109507 · Cited by 1

Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice

Li, S. B., Xu, Z., Ruan, W., Wang, X. J., Yu, H., Yi, M., & Fu, P. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02711-9 · Cited by 1

Artificial intelligence advancements in monoclonal antibody development technology

Ammar, M., Samsonov, M. Y., Gurylina, E., & Bayzigitov, D. R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1802038 · Cited by 1

Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure–activity relationships, and ADMET liabilities

Zhao, W., Bie, B., Wang, J., Liu, X., Fang, H., & Niu, R. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03588-5 · Cited by 1

Recent advances in Camptothecin-derived antibody-drug conjugates

Yu, X., Yu, D., Wang, Y., Jiang, B., & Chen, H. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118737 · Cited by 1

Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions

Bradford, C. R., Sreeram, M. P., Rao, K. N., Guntinas‐Lichius, O., Saba, N. F., & Ferlito, A. (2026) · Head & Neck · doi:10.1002/hed.70385 · Cited by 1

Immunotherapy in cancer: Mechanisms and strategies to overcome resistance

Yang, H., Yang, Z., Wang, X., Patel, H. H., Wu, Z., Ashby, C. R., Wang, W., & Chen, Z. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101447 · Cited by 1

From barriers to cloud-based regulatory collaboration: An industry perspective on accelerating innovation in pharmaceutical manufacturing

Cauchon, N. S., Algorri, M., Ahluwalia, K., Kirwan, J. P., Griswold, B., Abernathy, M. J., & Pawbake, G. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104419 · Cited by 1

Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination

Liu, X.-T., Tang, F., & Huang, W. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01867-w · Cited by 1

Antibody-drug conjugates against multidrug-resistant cancers: Biomarker-guided patient selection, payload engineering, linker chemistry, and bystander effects

Li, R., Chen, X., Huang, Q., Ling, H.-J., Gong, K., & Chen, Z. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218753 · Cited by 3

Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance

Liu, J., Farrow, M., Hsing, S. S., Cosman, R., Lemech, C., Teng, C. T., Pal, A., Nindra, U., Parsonson, A. O., Park, J., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0733 · Cited by 1

High-payload antibody-oligonucleotide-drug conjugates (AODC) for targeted tumor chemo-immunotherapy

Zhang, S., Ye, R., Shi, T., Deng, C., Chang, L., Ren, Q., Zhang, P., Xu, C., & Zhong, Z. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115209 · Cited by 1

Trastuzumab Deruxtecan in Metastatic Urothelial Carcinoma with NGS-Detected ERBB2 Amplification: A Four-Patient Real-World Case Series

Lorenzo, G. D., Lorenzo, S. D., Verde, A., Strianese, O., Leo, L., & Buonerba, C. (2026) · Current Oncology · doi:10.3390/curroncol33080456 · Cited by 1

Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives

Zheng, R., Li, S., Zhang, Z., Niu, M., Fei, J., Zhang, J., Zhou, J., Wu, K., Yi, M., & Li, T. (2026) · MedComm · doi:10.1002/mco2.70897 · Cited by 1

SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis

Zhang, H., Zhang, J., Su, C., Wang, Y., Liu, C., Dou, Y., Liu, J., Zhao, W., Liu, S., Cong, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1817351 · Cited by 1

A binding-to-release strategy for targeted anticancer drug delivery

Wen, Z., Xu, M., Yan, Z., Kong, Z., Wang, Y., Liu, P., Chen, J., Liu, Y., Cui, X., Cen, T., et al. (2026) · Nature · doi:10.1038/s41586-026-10971-0 · Cited by 2

Aptamer-functionalized systems for precision oncology: From molecular recognition to diagnosis and therapy

Wu, G., Zhang, Y., Fu, T., He, J., Liu, X., & Tan, W. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.119135 · Cited by 1

Real-world pharmacovigilance signals of antibody–drug conjugates: reporting patterns by payload, linker, target, and sex in FAERS

Chen, Z., Song, J., Chen, M., Zhu, C., Li, L., & Lv, Z. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05898-2 · Cited by 1

From antibody to small molecule carriers: Targeted conjugation under prodrug constraints

Schulz, J. M., Chen, J. Y., Edwards, C. C., Gassman, N. R., Schürer, S. C., & Reynolds, R. C. (2026) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2026.07.002 · Cited by 1

Single-cell and spatial profiling of cysteine cathepsins identifies tumor states relevant to antibody-drug conjugates in breast cancer

Ćwilichowska-Puślecka, N., Malek-Chudzik, N., Gorzeń, O., Puślecki, T., Mlost, J., Nguyen, J., Dołęga-Kozierowski, B., Kasprzak, P., Sopel, M., Groborz, K. M., et al. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02397-3 · Cited by 1

Mitochondria-targeted tetraoxanes initiate lipid peroxidation to drive ferroptosis and tumor suppression

Pan, Z., Wong, M.-K., Lu, Y., Mao, J., Wang, F., Gu, X., Huang, K., Shi, T., Wu, T. W., Zhu, Y., et al. (2026) · Cell · doi:10.1016/j.cell.2026.09.040 · Cited by 1

Antibody–Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab–Vedotin Exert Anti-Lymphoma and Immunostimulating Effects

Morelli, F., Matis, S., Benelli, R., Salvini, L., Zocchi, M. R., & Poggi, A. D. (2024) · Cells · doi:10.3390/cells13100862 · Cited by 1

Highly Active Oligoethylene Glycol Pleuromutilins via Systematic Linker Synthesis/One-Pot Attachment and a Microscale Solubility Method

Breiner, L. M., Słowiński, R., & Lowell, A. N. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c02683 · Cited by 1

The novel strategy of Bispecific Antibody-Drug Conjugates (BsADCs) in Cancer Therapy

Li, Z., Yu, L., Wang, L., & Zheng, H. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2024.la19333 · Cited by 1

Evaluation of Multispecific Drugs Based on Patient‐Derived Immunocompetent Tumor Organoids

Zhao, Z., Wu, X., Zhang, T., Zhou, M. R., Liu, S., Yang, R. L., & Li, J. (2025) · ChemBioChem · doi:10.1002/cbic.202400731 · Cited by 1

A novel DNA sequence-selective, guanine mono-alkylating ADC payload suitable for solid tumour treatment

Andriollo, P., di Mascio, D. M., Jackson, P. J., Hasan, M. M., Pysz, I., Procopiou, G., Fox, K. R., Rahman, K. M., & Thurston, D. E. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md01040j · Cited by 1

Site-directed antibodies targeting driver mutations of the KRAS protein

Li, X., Mendez, Q. M., Chapados, C. D., Acca, F. E., Driscoll, H., Oliveira, J., Liu, J., Jones, K. S., Ferguson, M., Wallace, R. L., et al. (2025) · New Biotechnology · doi:10.1016/j.nbt.2025.04.003 · Cited by 1

An antibody-drug conjugate targeting soluble and membrane-bound TGFα is effective against pancreatic tumors

Romero-Pérez, I., Montero, J. C., Redondo-Puente, M., Gómez-García, M. D. C., Morell, M., Capellá, G., & Pandiella, A. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03421-8 · Cited by 1

abCAN: a Practical and Novel Attention Network for Predicting Mutant Antibody AffinityPreprint

Gong, C., Shen, Y., Liu, H., & Ming, W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.02.625958 · Cited by 1

Rewiring Oncogenic Transcriptional Complexes with Domain-ALTerAtion Chimeras (DALTACs) in Prostate CancerPreprint

Luo, J., Yang, J., Tien, J. C.-Y., Wang, M., Das, S., Wang, X., Young, E., Tošović, J., Mannan, R., Xiang, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.24.720638 · Cited by 1

Peptide Tag-nology for Preparation of Site-Specific Antibody–Drug Conjugates

Ringaci, A., & Grinstaff, M. W. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00154 · Cited by 1

WITHDRAWN: Using antibody-drug conjugates for anti-tumor immunity

Katrini, J., Scafetta, R., Boldrini, L., Ascione, L., Santoro, C., Guidi, L., Valenza, C., Trapani, D., & Curigliano, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00006-0

Consequences of Immunoglobulin Domain-Containing Protein Retro-ProteinsPreprint

Terry, M., Hurtado, A., Mendoza, C., Vargas, L., Davila, I., Steele, T., Gonda, A., & Mizrachi, D. (2024) · Preprints.org · doi:10.20944/preprints202406.1001.v1

Cellular and transcriptional profiles of peripheral blood mononuclear cells pre-vaccination predict immune response to preventative MUC1 vaccinePreprint

Yuan, D. Y., McKeague, M. L., Raghu, V. K., Schoen, R. E., Finn, O. J., & Benos, P. V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.14.598031

Metastasiertes Melanom: Neue Kombinationstherapien und Studienansätze

Scheel, C., & Dervenis, V. (2024) · Trillium Krebsmedizin · doi:10.47184/tk.2024.03.2

Aktuelle Standards und vielversprechende Innovationen in der medikamentösen Zweitlinientherapie des metastasierten kleinzelligen Lungenkarzinoms (ED-SCLC)

Pogorzelski, M., & Schüler, M. (2024) · Die Onkologie · doi:10.1007/s00761-024-01579-y

Identification of a Novel Transasparaginase Activity of Bacillus subtilis (bTG) for Sequence-Specific Bioconjugation

Flamme, M., Göhring, R., Zamarbide, D., Bon, C., Vissières, A., Basler, A., Miranda, D., Kneuer, R., & Mann, G. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00306

Using antibody-drug conjugates for anti-tumor immunity

Katrini, J., Scafetta, R., Boldrini, L., Ascione, L., Santoro, C., Guidi, L., Valenza, C., Trapani, D., & Curigliano, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.90006-7

Anticorps conjugués et anticorps bispécifiques dans le cancer du poumon : un nouvel espoir ?

Cani, M., Lefevre, A., & Remón, J. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00092-2

Antibody-Drug Conjugates Targeting Ssea-4 Inhibits Tumor Growth of Ssea-4 Positive Breast CancerPreprint

Usama, M., Hsu, Y.-C., Safaei, M., Chen, C., Han, K. H., Ho, Y., Yamaguchi, H., Li, Y., Hung, M., Wong, C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4990997

COP II-mediated ER-to-Golgi transport is a bottleneck for IgNAR-Fc production in the Chinese hamster ovary cell expression system

Lyu, X., Yamano, N., Koga, Y., & Ōmasa, T. (2024) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2024.10.012

Integrating targeting and drug retention: A promising approach for cancer treatment

Wang, S., & Zhong, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.016

Benzyl Ammonium Carbamates Undergo Two‐Step Linker Cleavage and Improve the Properties of Antibody Conjugates

Li, X., Patel, N. L., Kalen, J. D., & Schnermann, M. J. (2024) · Angewandte Chemie · doi:10.1002/ange.202417651

Deciphering Features of Metalloprotease Cleavage Targets Using Protein Structure PredictionPreprint

Chung, D. S., Park, J., Choi, W. J., & Hong, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.13.632885

AACDB: Antigen-Antibody Complex Database — a Comprehensive Database Unlocking Insights into Interaction InterfacePreprint

Zhou, Y., Liu, W., Huang, Z., Gou, Y., Liu, S., Jiang, L., Yang, Y., & Huang, J. H. (2025) · eLife · doi:10.7554/elife.104934.1

Identifying Molecular Mechanisms of Cinnamomum cassia in the Treatment of Osteoporosis Based on Network Pharmacology and Validations

Sun, X., & Fei, J. (2025) · Pharmacognosy Magazine · doi:10.1177/09731296241312458

Macromolecular Diamidobenzimidazole Conjugates Activate STINGPreprint

Arora, K., Sheehy, T. L., Schulman, J. A., Kimmel, B. R., McAtee, C., Bharti, V., Weaver, A. M., & Wilson, J. T. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.21.634206

Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target expressionPreprint

Wood, N. E., Cengiz, A., Gao, M., Ratushny, A. V., & Straube, R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.31.635847

A bioengineered antibody conjugate reshape dendritic cell viability for immune-tolerance modulation

Chen, X., Wang, Y., Xu, T., Liu, H., Ye, X., Wang, P. G., Qin, X., Yang, S., Ning, W., Zeng, H., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.160431

Proof of Concept for the Single-Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular OncoproteinPreprint

Byun, K. T., Kim, B., Lee, I., Cho, J., Hwang, Y., Cheon, S. Y., Kang, H. C., Kim, C. G., Byun, J. W., Paeng, J. C., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5145344

Antibody–drug conjugates in rare genitourinary tumors: review and perspectives

Kydd, A. R., Sarwar, M. S., Atiq, S. O., Chelluri, R. R., Gurram, S., Chandran, E. B. A., Simon, N. I., Stukes, I., Weng, S., Yousefi-Rad, A., et al. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001141

Deuterium Substitution at the Intolerable Site as a Strategy to Mitigate the Toxicity of Camptothecin DerivativesPreprint

Chen, H., Yu, X., Sun, Z., Liu, J., Huangfu, S., Cheng, Q., Chen, J., & Jiang, B. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5220240

AACDB: Antigen-Antibody Complex Database — a Comprehensive Database Unlocking Insights into Interaction InterfacePreprint

Zhou, Y., Liu, W., Huang, Z., Gou, Y., Liu, S., Jiang, L., Yang, Y., & Huang, J. H. (2025) · eLife · doi:10.7554/elife.104934.2

Drug Delivery Modalities and Mechanisms

Tam, Y. T., Migliozzi, M. M., Tesar, D. B., Famili, A., Wecksler, A. T., Wichner, S. M., Sreedhara, A., & Shatz-Binder, W. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch20

Chemoproteomics Approaches for Diverse Modalities

Eberl, H. C., Knecht, S., Queisser, M. A., & Bantscheff, M. (2025) · Wiley eBooks · doi:10.1002/9781394236145.ch19

Introduction

Guarnaccia, A. D., Sandoval, W. N., & Lill, J. R. (2025) · doi:10.1002/9781394236145.ch1

The Mechanism and Research Progress of Antibody-Drug Conjugates in the Treatment of Bladder Tumors

严, 聪. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1571979

Next stop, precision: targeted therapies for Staphylococcus aureus infections

Hernández, F. J. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2528416

Rapid review of drug induced Stevens Johnson Syndrome case reports from 2003 to 2023: Trends among monoclonal antibodies and systemic immunosuppressant therapy

Gossell‐Williams, M., McLaren, G., Clarke, R., Douglas, S., Gayle, D., & Guthrie, K. (2025) · International Journal of Risk & Safety in Medicine · doi:10.1177/09246479251368022

A Self‐Assembled Protein Platform for Plug‐and‐Play Customization of Multivalent Artificial Antibodies and Antibody‐Drug Conjugates

Chen, Y., Huang, Y., Wang, S., Wang, X., Lu, H., Chen, J., Li, J., Chen, Z., Zhao, L., She, T., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202506426

Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram RadiotheranosticsPreprint

Lee, W. H., Doda, S. R., Baidoo, K. E., Nambiar, D., Chung, J., Adler, S., Edmondson, E. F., Ueda, Y., Omiya, S., Li, X., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.11.675134

A Serum‐Stable Antimicrobial Peptide‐Based Delivery Platform for Selective Treatment of Nontargetable and Chemoresistant Tumors

Liu, T., Ke, L., Sun, R., Chen, X., Zhou, M., Bininda‐Emond, O. R. P., Ma, C., Jiang, Y., Wang, T., Shaw, C., et al. (2025) · Advanced Science · doi:10.1002/advs.202504710

NIR‐Activatable, Sequence‐Specific Metal‐Nucleic Acid Scaffolds for Responsive Uncaging

Sharma, A., Kshetri, M. B., Karna, D., Amin, M. A., Akter, S., Mao, H., & Zheng, Y. (2025) · Angewandte Chemie · doi:10.1002/ange.202514717

Platelets as Carriers for Antitumor Therapy

Bethel, C. J., & Malvestiti, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_19

Next Generation Antibody–Drug Conjugates: Molecular Design Innovations And Overcoming Resistance – A Comprehensive Review

Hari Nandhini.A, D. S. S. M. B. R. (2025) · Vascular and Endovascular Review · doi:10.64149/j.ver.8.16s.217-224

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Metrangolo, V., & Engelholm, L. H. (2024) · Cancers · doi:10.3390/cancers16020447 · Cited by 77

Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

Wu, D., Yang, K., He, R., Yin, R., & Shui, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1669592 · Cited by 25

Antibody-drug conjugates: mechanism, progress and future directions of cancer targeted therapy

Li, M., Wu, G., Chen, B., Zheng, Z., Ning, X., Li, J., De, Z., Li, J., & Song, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02817-0

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209